

BIOGEN IDEC INC  
Form 8-K  
October 27, 2004

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 27, 2004**

**Biogen Idec Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-19311**  
(Commission  
File Number)

**33-0112644**  
(I.R.S. Employer  
Identification No.)

**14 Cambridge Center, Cambridge, Massachusetts**  
(Address of principal executive offices)

**02142**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 679-2000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

ITEM 2.02 Results of Operations and Financial Condition.

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE DATED OCTOBER 27, 2004

---

**Table of Contents**

**ITEM 2.02 Results of Operations and Financial Condition.**

The press release attached as Exhibit 99.1 includes information with respect to the following: (a) the Registrant's adjusted non-GAAP earnings per share and net income for the third quarter and the first nine months of 2004, and (b) the Registrant's adjusted pro forma non-GAAP earnings per share, net income and revenues for the third quarter and the first nine months of 2003. These are non-GAAP financial measures.

The non-GAAP financial measures for the third quarter and the first nine months of 2004 exclude non-operational and unusual activities and transactions. The non-GAAP financial measures for the third quarter and the first nine months of 2003 include revenue and expenses from the former Biogen, Inc. and exclude non-operational and unusual activities and transactions of the former Biogen, Inc. and IDEC Pharmaceuticals Corporation.

Management believes that the non-GAAP financial measures provide useful information to investors. In particular, management believes that they allow investors to monitor and evaluate the Registrant's ongoing operating results and trends and gain a better understanding of the Registrant's business, period-to-period performance, and prospects for future performance.

This press release is being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that Section, nor shall such documents be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biogen Idec Inc.**

By:                   /s/ Thomas J. Bucknum

Thomas J. Bucknum  
Executive Vice President, General Counsel

Date: October 27, 2004

---

**Table of Contents**

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
99.1	The Registrant's Press Release dated October 27, 2004.